Skip to main content
    X

    Xenon Pharmaceuticals Inc (XENE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $39.26
    -1.22 (-3.01%)

    Market Cap: $3.98B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xenon Pharmaceuticals Inc (XENE) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Xenon Pharmaceuticals (XENE) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Xenon Pharmaceuticals reported EPS of -$1.11, above the -$1.14 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -5.53%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.17
    Range-$1.32 - -$0.89
    18 analysts
    Revenue Consensus
    $919.02K
    RangeN/A
    16 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$1.21
    Range-$1.30 - -$1.02
    5 analysts
    EPS Revisions
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.25+3.0%
    60d ago-$1.25+3.0%
    30d ago-$1.25+3.0%
    7d ago-$1.25+3.0%
    Current-$1.21
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts

    Next Report

    XENE has an expected report date of Feb 24, 2027.

    XENE Earnings Call

    The latest XENE earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, XENE beat 21 and missed 19. The widest gap in the table came in the quarter ended Dec 31, 2017, when EPS landed 309.09% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$1.11-$1.14-$1.29 - -$0.94+2.63%BeatN/A111 up, 0 downNov 9, 2026N/A
    Jun 30, 2026-$1.11-$1.16-$1.46 - -$0.92+4.31%BeatN/A147 up, 4 downAug 6, 2026N/A
    Mar 31, 2026-$1.17-$1.20-$1.32 - -$1.03+2.50%BeatN/A133 up, 3 downMay 7, 2026N/A
    Dec 31, 2025-$1.31-$1.20-$1.38 - -$1.10-9.17%MissN/A157 up, 3 downFeb 26, 2026N/A
    Sep 30, 2025-$1.15-$1.16-$1.27 - -$0.99+0.86%BeatN/A132 up, 11 downNov 3, 2025N/A
    Jun 30, 2025-$1.07-$0.99-$1.10 - -$0.80-8.08%MissN/A13N/AAug 11, 2025N/A
    Mar 31, 2025-$0.83-$0.90-$0.98 - -$0.79+7.78%BeatN/A131 up, 0 downMay 12, 2025$7.50M
    Dec 31, 2024-$0.84-$0.84-$0.95 - -$0.68-0.10%MissN/A126 up, 5 downFeb 27, 2025$2.52M
    Sep 30, 2024-$0.81-$0.79-$0.99 - -$0.62-2.53%MissN/A170 up, 0 downNov 12, 2024N/A
    Jun 30, 2024-$0.75-$0.68-$0.82 - -$0.62-10.29%MissN/A150 up, 0 downAug 8, 2024N/A
    Mar 31, 2024-$0.62-$0.65-$0.77 - -$0.56+4.62%BeatN/A160 up, 0 downMay 9, 2024N/A
    Dec 31, 2023-$0.64-$0.76-$0.99 - -$0.54+15.79%BeatN/A171 up, 0 downFeb 29, 2024$5.38M
    Sep 30, 2023-$0.73-$0.75-$0.89 - -$0.54+2.67%BeatN/A150 up, 0 downNov 8, 2023N/A
    Jun 30, 2023-$0.72-$0.67-$0.78 - -$0.52-7.46%MissN/A150 up, 1 downAug 9, 2023N/A
    Mar 31, 2023-$0.63-$0.60-$0.73 - -$0.41-5.00%MissN/A151 up, 0 downMay 9, 2023N/A
    Dec 31, 2022-$0.57-$0.58-$0.78 - -$0.39+1.72%BeatN/A150 up, 0 downMar 1, 2023$8766
    Sep 30, 2022-$0.57-$0.53-$0.69 - -$0.37-7.55%MissN/A120 up, 0 downNov 8, 2022$132000
    Jun 30, 2022-$0.55-$0.50N/A-10.00%MissN/AN/A0 up, 1 downAug 9, 2022$536000
    Mar 31, 2022-$0.35-$0.41-$0.53 - -$0.29+14.63%BeatN/A90 up, 0 downMay 10, 2022$8.77M
    Dec 31, 2021-$0.48-$0.37-$0.67 - -$0.01-29.73%MissN/A9N/AMar 1, 2022$3.74M
    Sep 30, 2021-$0.36-$0.44-$0.54 - $0.05+18.18%BeatN/A9N/ANov 10, 2021$8.12M
    Jun 30, 2021-$0.51-$0.49-$0.62 - -$0.34-4.08%MissN/A8N/AAug 11, 2021$2.22M
    Mar 31, 2021-$0.42-$0.39-$0.63 - -$0.38-7.69%MissN/A7N/AMay 11, 2021$4.36M
    Dec 31, 2020-$0.34-$0.40N/A+15.00%BeatN/AN/AN/AMar 1, 2021$5.15M
    Sep 30, 2020-$0.25-$0.17-$0.34 - $0.26-47.06%MissN/A7N/ANov 5, 2020$6.55M
    Jun 30, 2020$0.00-$0.20-$0.39 - -$0.07+97.55%BeatN/A6N/AAug 6, 2020$13.38M
    Mar 31, 2020-$0.22-$0.31-$0.43 - -$0.15+29.03%BeatN/A5N/AMay 21, 2020$7.08M
    Dec 31, 2019-$0.42-$0.48-$0.52 - -$0.45+12.50%BeatN/A3N/AMar 9, 2020$3.33M
    Sep 30, 2019-$0.33-$0.46-$0.61 - -$0.41+28.26%BeatN/A4N/ANov 5, 2019$3.50M
    Jun 30, 2019-$0.37-$0.45-$0.48 - -$0.43+17.78%BeatN/A3N/AAug 6, 2019N/A
    Mar 31, 2019-$0.42-$0.37-$0.37 - -$0.35-13.51%MissN/A2N/AMay 7, 2019N/A
    Dec 31, 2018-$0.29-$0.37-$0.38 - -$0.36+21.62%BeatN/A2N/AMar 6, 2019$6.00M
    Sep 30, 2018-$0.63-$0.40N/A-57.50%MissN/A2N/ANov 6, 2018N/A
    Jun 30, 2018-$0.45-$0.49-$0.49 - -$0.49+8.16%BeatN/A2N/AAug 7, 2018N/A
    Mar 31, 2018-$0.46-$0.48-$0.49 - -$0.47+4.17%BeatN/A2N/AMay 8, 2018N/A
    Dec 31, 2017-$0.45-$0.11-$0.44 - $0.22-309.09%MissN/A2N/AMar 7, 2018$16000
    Sep 30, 2017-$0.43-$0.39N/A-10.26%MissN/AN/AN/ANov 7, 2017$264000
    Jun 30, 2017-$0.41-$0.39N/A-5.13%MissN/AN/AN/AAug 3, 2017$15000
    Mar 31, 2017-$0.42-$0.38N/A-10.53%MissN/AN/AN/AMay 9, 2017$16000
    Dec 31, 2016-$0.32-$0.42N/A+23.81%BeatN/AN/AN/AMar 8, 2017$376000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$4.36, after -$3.02 the year before. It was -$1.48 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$4.36N/A
    Dec 31, 2024-$3.02N/A
    Dec 31, 2023-$2.72N/A
    Dec 31, 2022-$2.04N/A
    Dec 31, 2021-$1.77N/A
    Dec 31, 2020-$0.81N/A
    Dec 31, 2019-$1.54N/A
    Dec 31, 2018-$1.83N/A
    Dec 31, 2017-$1.71N/A
    Dec 31, 2016-$1.48N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 15 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,50615
    2026Q2Jun 30, 20268,93416
    2026Q1Mar 31, 20267,44415
    2025Q3Sep 30, 20258,04516
    2025Q2Jun 30, 20256,14011
    2025Q1Mar 31, 20258,73615
    2024Q4Dec 31, 20248,19911
    2024Q3Sep 30, 20247,78219

    2026Q3 Earnings Call

    Opening remarks

    Colleen Alabiso Senior Vice President of Corporate Affairs Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's third quarter 2026 financial and operating results. Joining me today are Ian Mortimer, President and Chief Executive Officer; Dr. Chris Kenney, Chief Medical Officer; Darren Cline, Chief Commercial Officer; and Tucker Kelly, Chief Financial Officer. After completing our prepared remarks today, we will open the call up for your questions. Please be advised that during this call, we will make a number of forward-looking statements, including statements regarding the status of and potential results from clinical trials; the potential efficacy, safety profile, and future development plans in current and anticipated indications; addressable market; regulatory success and commercial potential of our and our partners' product candidates; the strength of our clinical trial designs; our ability to successfully develop and achieve milestones in our clinical development programs, including the anticipated filing of INDs or equivalent and NDAs; the timing and results of our interactions with regulators; our ability to successfully obtain regulatory approvals; anticipated timing of top-line data readouts for our clinical trials of azetukalner; and our expectation that we will have sufficient cash to fund operations into 2029. Today's press release summarizing Xenon's third quarter financial results and the accompanying quarterly report on Form 10-Q will be made available under the Investors section of our website at xenon-pharma.com and filed with the SEC and on SEDAR+. I'll now turn the call over to Ian.

    Ian Mortimer President and Chief Executive Officer Thank you, Colleen, and good afternoon to everyone joining us today. We're excited to recap another productive quarter for Xenon as we make continued progress toward becoming a fully integrated neuroscience company delivering life-changing medicines to patients. Over the last few months, we remained focused on three key areas: first, advancing azetukalner, or AZK, toward potential FDA approval and launch in the U.S. for the treatment of focal seizures and building our commercial infrastructure and launch plans. Second, broadening the therapeutic opportunities for AZK beyond focal seizures by progressing our additional Phase III epilepsy studies, as well as completing enrollment in our first Phase III neuropsychiatry study, X-NOVA2. And third, expanding our pipeline through advancement of our promising early-stage assets, including two of our pain candidates targeting Nav1.7 and Kv7, which we recently announced will be moving to Phase II proof-of-concept studies in acute pain based on positive Phase I data. Following the submission of our New Drug Application, or NDA, to the FDA in the third quarter, we're full steam ahead on preparing for the potential approval and launch of AZK. Our NDA package includes strong scientific evidence from two pivotal, randomized, double-blind, placebo-controlled trials in focal seizures, including the Phase IIb X-TOLE study and the Phase III X-TOLE2 study.

    Frequently Asked Questions About XENE

    When is Xenon Pharmaceuticals's next earnings date?

    Xenon Pharmaceuticals's next earnings report is expected for Feb 24, 2027.

    Did XENE beat earnings estimates last quarter?

    Yes. Xenon Pharmaceuticals reported EPS of -$1.11 for the quarter ended Sep 30, 2026, above the -$1.14 estimate, a 2.63% surprise.

    What EPS do analysts expect from XENE next quarter?

    The consensus EPS estimate for Xenon Pharmaceuticals for the quarter ending Dec 31, 2026 is -$1.17 from 18 analysts, with estimates from -$1.32 to -$0.89.

    How often does XENE beat earnings estimates?

    Xenon Pharmaceuticals beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.09%.